A new frontier: FDA approvals for gene therapy in sickle cell disease.
作者信息
Leonard Alexis, Tisdale John F
机构信息
Department of Hematology, St. Jude Children's Research Hospital, Memphis, TN, USA.
Cellular and Molecular Therapeutics Branch, National Heart, Lung, and Blood Institute and National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA.
出版信息
Mol Ther. 2024 Feb 7;32(2):264-267. doi: 10.1016/j.ymthe.2024.01.015. Epub 2024 Jan 20.
Abstract
摘要
相似文献
1
A new frontier: FDA approvals for gene therapy in sickle cell disease.
Mol Ther. 2024 Feb 7;32(2):264-267. doi: 10.1016/j.ymthe.2024.01.015. Epub 2024 Jan 20.
2
Approval of the First CRISPR-Cas9 Gene Editing Therapy for Sickle Cell Disease.
Clin Chem. 2024 Oct 3;70(10):1298. doi: 10.1093/clinchem/hvae038.
3
Food and Drug Administration Approval of Glutamine for Sickle Cell Disease: Success and Precautions in Glutamine Research.
JPEN J Parenter Enteral Nutr. 2017 Aug;41(6):912-917. doi: 10.1177/0148607117727271. Epub 2017 Aug 31.
4
Recent and anticipated novel drug approvals for 2023 and 2024.
Am J Health Syst Pharm. 2023 Nov 22;80(23):1729-1732. doi: 10.1093/ajhp/zxad220.
5
Gene therapy targets sickle-cell disease.
Nature. 2018 Dec;564(7735):S12-S13. doi: 10.1038/d41586-018-07646-w.
6
An Ethical and Financial Obligation for Sickle Cell Disease Gene Therapy in the United States.
Ann Intern Med. 2024 Jan;177(1):85-86. doi: 10.7326/M23-2428. Epub 2023 Dec 5.
7
Emerging disease-modifying therapies for sickle cell disease.
Haematologica. 2019 Sep;104(9):1710-1719. doi: 10.3324/haematol.2018.207357. Epub 2019 Aug 14.
8
Sickle Cell Disease Approvals Include First CRISPR Gene Editing Therapy.
JAMA. 2024 Jan 23;331(4):280. doi: 10.1001/jama.2023.26113.
9
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-Thalassemia.
Med Sci Monit. 2024 Mar 1;30:e944204. doi: 10.12659/MSM.944204.
10
Sickle cell disease: progress towards combination drug therapy.
Br J Haematol. 2021 Jul;194(2):240-251. doi: 10.1111/bjh.17312. Epub 2021 Jan 20.
引用本文的文献
1
Bioengineering approaches to trained immunity: Physiologic targets and therapeutic strategies.
Elife. 2025 Jul 23;14:e106339. doi: 10.7554/eLife.106339.
2
Hospital Readmissions Among People With Sickle Cell Disease.
JAMA Netw Open. 2025 Jun 2;8(6):e2517974. doi: 10.1001/jamanetworkopen.2025.17974.
3
Clinical advances in gene, cell, and RNA therapies.
Mol Ther. 2025 Jun 4;33(6):2311. doi: 10.1016/j.ymthe.2025.05.012. Epub 2025 May 20.
4
Comparative Proteomic Analysis Reveals Altered Ciliary Proteins in Sickle Cell Disease.
J Proteome Res. 2025 Jun 6;24(6):2981-2995. doi: 10.1021/acs.jproteome.5c00168. Epub 2025 May 15.
5
From bench to bedside: the future of stable lentiviral packaging cell lines in gene therapy.
Gene Ther. 2025 Apr 26. doi: 10.1038/s41434-025-00537-6.
6
Multilayered HIV-1 resistance in HSPCs through CCR5 Knockout and B cell secretion of HIV-inhibiting antibodies.
Nat Commun. 2025 Apr 1;16(1):3103. doi: 10.1038/s41467-025-58371-8.
7
Balancing benefits and burdens: a systematic review on ethical and social dimensions of gene and cell therapies for hereditary blood diseases.
BMC Med Ethics. 2025 Mar 14;26(1):36. doi: 10.1186/s12910-025-01188-3.
8
Epigenetic regulation in muscle-invasive urothelial carcinoma of the bladder in the dog, a translational model of human cancer.
Vet Oncol. 2024;1. doi: 10.1186/s44356-024-00011-2. Epub 2024 Nov 20.
9
Virus-free CRISPR knockin of a chimeric antigen receptor into KLRC1 generates potent GD2-specific natural killer cells.
Mol Ther. 2025 Mar 5;33(3):1014-1030. doi: 10.1016/j.ymthe.2025.01.024. Epub 2025 Jan 14.
10
Viral and Non-Viral Systems to Deliver Gene Therapeutics to Clinical Targets.
Int J Mol Sci. 2024 Jul 4;25(13):7333. doi: 10.3390/ijms25137333.
本文引用的文献
1
Human genetic diversity alters off-target outcomes of therapeutic gene editing.
Nat Genet. 2023 Jan;55(1):34-43. doi: 10.1038/s41588-022-01257-y. Epub 2022 Dec 15.
2
Lovo-cel gene therapy for sickle cell disease: Treatment process evolution and outcomes in the initial groups of the HGB-206 study.
Am J Hematol. 2023 Jan;98(1):11-22. doi: 10.1002/ajh.26741. Epub 2022 Oct 10.
3
Increased incidence of hematologic malignancies in SCD after HCT in adults with graft failure and mixed chimerism.
Blood. 2022 Dec 8;140(23):2514-2518. doi: 10.1182/blood.2022017960.
4
Acute Myeloid Leukemia Case after Gene Therapy for Sickle Cell Disease.
N Engl J Med. 2022 Jan 13;386(2):138-147. doi: 10.1056/NEJMoa2109167. Epub 2021 Dec 12.
5
CRISPR-Cas9 to induce fetal hemoglobin for the treatment of sickle cell disease.
Mol Ther Methods Clin Dev. 2021 Oct 1;23:276-285. doi: 10.1016/j.omtm.2021.09.010. eCollection 2021 Dec 10.
6
Leukemia after gene therapy for sickle cell disease: insertional mutagenesis, busulfan, both, or neither.
Blood. 2021 Sep 16;138(11):942-947. doi: 10.1182/blood.2021011488.
7
A pause in gene therapy: Reflecting on the unique challenges of sickle cell disease.
Mol Ther. 2021 Apr 7;29(4):1355-1356. doi: 10.1016/j.ymthe.2021.03.010. Epub 2021 Mar 19.
8
Building access to care in adult sickle cell disease: defining models of care, essential components, and economic aspects.
Blood Adv. 2020 Aug 25;4(16):3804-3813. doi: 10.1182/bloodadvances.2020001743.
9
Sickle cell anemia, a molecular disease.
Science. 1949 Apr 29;109(2835):443.
10
Therapeutic haemoglobin synthesis in beta-thalassaemic mice expressing lentivirus-encoded human beta-globin.
Nature. 2000 Jul 6;406(6791):82-6. doi: 10.1038/35017565.
Zotero 插件